Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Saturday, October 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. announced positive three-year follow-up results from its Phase 1b C-800-01 trial, which evaluated the combination of botensilimab and balstilimab in recurrent ovarian cancer. The trial involved over 400 patients and reported an estimated 48% survival rate. These findings highlight the potential of this immuno-oncology therapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • 48% estimated three-year survival rate reported.
  • Results from a significant Phase 1b trial with over 400 patients.
  • Combination therapy shows promise in recurrent ovarian cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
3.1%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Botensilimab
Phase 2 · Colorectal Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by

Frequently Asked Questions

What is the survival rate reported by Agenus?

Agenus reported a 48% estimated three-year survival rate.

What trial did Agenus announce results from?

Agenus announced results from its Phase 1b C-800-01 trial.

What therapies were evaluated in the trial?

The trial evaluated botensilimab (BOT) and balstilimab (BAL).

How many patients were involved in the study?

The study involved over 400 patients.

ShareAdd on Google
Tags: AGEN Agenus ovarian cancer botensilimab balstilimab Phase 1b
Last updated: Oct 3, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BotensilimabPhase 2
Colorectal Cancer →

Catalyst track record

+121%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →